The limited availability of patient tissue samples poses a constant challenge for omics researchers, particularly in determining which analyses are feasible based on sample input requirements. Existing parallel workflows for multi-omic analyses have yielded valuable insights but are often restricted to the analysis of one or two post-translational modifications. The MONTE workflow, described by the Carr lab in a recent study published in Nature Communications, addresses these limitations.

The United States National Cancer Institute (NCI) and Taiwan are pleased to announce the signing of an extension to their memoranda of understanding (MOUs) for proteogenomics cancer research with Academia Sinica and Chang Gung University. This extension marks a renewed commitment to the collaboration of their efforts to expedite proteogenomics research and enhance care for individuals with cancer while simultaneously making research data widely accessible to the broader community as a global public good.

Glycosylation is a ubiquitous type of protein modification that is associated with biological functions and diseases, including cancer. Often found on cell surface or secreted into circulation, glycoproteins can be leveraged for diagnosis and treatment.

Clear cell renal cell carcinoma (ccRCC) is a common type of kidney cancer that originates from the cells of the renal tubules. Recent research has focused on identifying tumor-cell-specific markers to provide mechanistic insights into cancer etiology and support the development of novel targeted therapies, aiming to improve patient outcomes.

Despite unprecedented advances in the development of targeted- and immuno-therapies for various cancer types, pancreatic ductal adenocarcinoma (PDAC) remains a leading cause of cancer-related death worldwide. A comprehensive characterization of PDAC is critical for the development of new therapies and the improvement of patient outcomes. A key challenge affecting proteogenomic analysis of PDAC is that tumors typically have low neoplastic cellularity and heterogeneous composition.

Despite extensive clinical and scientific efforts, pancreatic ductal adenocarcinoma (PDAC) remains one of the leading causes of cancer-related deaths in Korea and around the world. Prior analyses of PDAC tissues have identified key genomic features of the disease, but proteomic signatures have not been characterized to the same extent.

Diffuse intrinsic pontine gliomas (DIPG) are a type of brain tumor that is extremely aggressive and have a historically poor prognosis. To improve these outcomes, the development of novel therapies and methods to measure their efficacy are critical.

The Applied Proteogenomics Organizational Learning and Outcomes (APOLLO) network is a cancer moonshot inspired initiative between the National Cancer Institute, the Department of Defense, and the Department of Veterans Affairs to incorporate proteogenomics into patient care as a way of looking beyond the genome. The APOLLO Team, led by Dr.

Renal cell carcinoma (RCC) is among the ten most diagnosed cancers worldwide for men and women and comprises a wide array of histologically and genetically defined subtypes involving the kidney. Clear cell RCC (ccRCC) accounts for ~75% of all RCC cases and the majority of renal cancer-associated deaths. High inter- and intra-tumoral heterogeneity in ccRCC represents a key clinical challenge in the molecular characterization of ccRCC and is a confounding factor for therapy selection.

Recently, Dr. Bing Zhang and his team from the Lester and Sue Smith Breast Center at Baylor College of Medicine were awarded a two-year funding opportunity to develop Cutting Edge Informatics Tools for the NIH Common Fund program Illuminating the Druggable Genome (IDG).